Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?

• click to rate

  Posted by Two Blokes Jul 28 - Filed in Stock - 1 view
  
  ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.